Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ADME and pharmacokinetic study of radiolabeled EMA401 in healthy male volunteers
NL-OMON44485Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of olodanrigan in Peripheral neuropathic pain and Neuralgia, sponsored by Novartis. Primary endpoints: Excretion and mass balance of total radioactivity, Pharmacokinetics of total radioactivity and 1 more. Started Jul 2017; status: active, not recruiting.
02
Drugs
olodanrigan
03
Conditions
Peripheral neuropathic painNeuralgia
Beyond the preview
Go deeper on NL-OMON44485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44485.